Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction

Malignant Biliary Obstruction Clinical Trial

— MBO—IR  

Official title:

Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01073514
• Other study ID #: TMU-CIH-IR-001
• Secondary ID: ChiCTR-ONC-00000
• Status: Recruiting
• Phase: N/A
• First received: February 21, 2010
• Last updated: December 21, 2015
• Start date: December 2009
• Est. completion date: December 2016

Study information

• Verified date: February 2010
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: YU HAI PENG, MD
• Phone: 13352070835
• Email: JIERUKE[@]YAHOO.COM.CN
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the "gold standard" for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.

Description:

We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion Criteria:

• Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Malignant Biliary Obstruction

Locations

Country	Name	City	State
China	Tianjin Medical University Cancer Institude and Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China,